Evaluation of the effect of the integrin-receptor antagonist Vedolizumab (VDZ) on intestinal barrier integrity and microbiota composition in patients with Inflammatory Bowel Disease

Project objectives

The study has the general objective of studying the effect of Vedolizumab, a selective antagonist of the intestinal α4β7 receptor, used as a therapy for patients suffering from inflammatory bowel disease (IBD), on intestinal permeability and on any changes in the faecal and mucosal microbiota . Furthermore, as a secondary objective, potential associations between clinical parameters and alterations of the mucosal barrier and microbiota in patients affected by IBD will be evaluated.

Start and end date

Project Manager

Coordinating institution of the project

Other Institutions involved

• Leuven Translational Research Center for Gastrointestinal Disorders. Gasthuisberg, Leuven, Belgium
• Human Microbiome Research Unit, Ospedale Pediatrico Bambino Gesù, Rome

Project funding source